8-K: MannKind to Acquire scPharmaceuticals in $360M Deal

MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. for an upfront cash payment of $5.35 per share plus contingent value rights up to $1.00 per share, expanding its presence in cardiometabolic medicine.

Summary

• MannKind Corporation will acquire scPharmaceuticals Inc. through a tender offer and subsequent merger, with scPharmaceuticals becoming a wholly-owned subsidiary of MannKind.
• The offer price is $5.35 per share in cash, plus one non-tradeable Contingent Value Right (CVR) per share, representing the right to receive up to an aggregate of $1.00 in cash based on specific milestones.
• Milestone 1 involves FDA approval of an Injection Product (SCP-111 delivered in an autoinjector or Self-Dose system), with payments of $0.75, $0.50, or $0.25 per CVR depending on approval date (by Sept 30, 2026, Dec 31, 2026, or June 30, 2027, respectively).
• Milestone 2 requires achievement of at least $110.0 million in worldwide net sales of all Injection Products and FUROSCIX Infusors in any trailing 12-month period ending prior to or including December 31, 2026, with payments of $0.25 per CVR for sales over $120.0 million, or $0.10-$0.25 for sales between $110.0 million and $120.0 million.
• The total consideration is up to $6.35 per share, valuing the equity at approximately $303 million at closing and up to $360 million in total deal value.
• The offer price represents a 36% premium to scPharmaceuticals' 90-trading day volume-weighted average price (VWAP) and up to a 31% premium to its closing price on August 22, 2025.
• scPharmaceuticals' President and CEO, John H. Tucker, and OrbiMed Advisors LLC, who collectively own approximately 11.5% of outstanding shares, have entered into Tender and Support Agreements to tender their shares.
• The offer is not subject to any financing condition.
• MannKind and Blackstone amended their strategic financing agreement to provide $175 million of additional funding for the acquisition.
• Upon closing, MannKind will repay and extinguish scPharmaceuticals' outstanding indebtedness under its credit facility with Perceptive and buy out Perceptive's revenue participation rights, estimated at an aggregate of $81 million (assuming a September 30, 2025 closing).
• The scPharmaceuticals Board of Directors unanimously approved the merger agreement and recommends that stockholders accept the offer.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to scPharmaceuticals shareholders and strategically diversifies MannKind's revenue base with a high-growth product in a large market. The financing is secured, and key stakeholders support the deal. While CVRs introduce some uncertainty, the upfront cash and strategic rationale are strong.

Positives

• scPharmaceuticals shareholders receive a significant premium: 36% to the 90-day VWAP and up to 31% to the closing price on August 22, 2025.
• The acquisition diversifies MannKind's revenue base with three commercial assets (Afrezza, FUROSCIX, V-Go) and Tyvaso DPI-related revenues, projecting an annualized run rate over $370 million based on Q2 2025 results.
• MannKind strategically expands into cardiorenal medicine, establishing a new cardiometabolic business alongside its orphan lung division.
• FUROSCIX addresses a significant unmet need in chronic heart failure (CHF) and chronic kidney disease (CKD), with an estimated total addressable market exceeding $10 billion in the U.S.
• scPharmaceuticals demonstrated strong commercial momentum with FUROSCIX, reporting $27.8 million in net sales for the first six months of 2025, a 96% year-over-year increase.
• The FUROSCIX ReadyFlow Autoinjector is on track for a Q3 2025 sNDA submission, which could reduce treatment time from five hours to less than 10 seconds, potentially unlocking additional market opportunities.
• MannKind's existing commercial infrastructure is well-positioned to accelerate FUROSCIX's market opportunity in CKD.
• MannKind has secured sufficient capital for the acquisition through an additional $175 million in funding from Blackstone.
• Key scPharmaceuticals stockholders, including the CEO and OrbiMed Advisors LLC, representing approximately 11.5% of outstanding shares, have committed to tendering their shares, indicating strong insider support for the transaction.

Negatives

• The Contingent Value Rights (CVRs) are non-tradeable, limiting liquidity and immediate value realization for the contingent portion of the consideration.
• There is no guarantee that Milestone 1 or Milestone 2 will be achieved, or that any CVR payments will be made, introducing uncertainty for the full $1.00 per share contingent value.
• The acquisition involves a substantial repayment and buyout of scPharmaceuticals' existing debt and revenue participation rights, estimated at $81 million.
• The transaction may cause disruption, potentially making it more challenging to maintain relationships with employees, collaborators, vendors, and business partners.
• Management's attention may be diverted from ongoing business operations during the integration process.
• The CVR payment for Milestone 1 decreases if FDA approval is delayed, and Milestone 2 is dependent on achieving specific net sales targets by a defined date.

Risks

• Uncertainties regarding the timing and completion of the tender offer and the merger.
• Uncertainties as to the percentage of scPharmaceuticals' stockholders who will tender their shares in the offer.
• The possibility that competing offers (Alternative Proposals) for scPharmaceuticals may emerge.
• The risk that various closing conditions for the tender offer or the merger may not be satisfied or waived, including the failure to receive required regulatory approvals.
• Risks related to scPharmaceuticals' liquidity during the pendency of the tender offer and merger, or in the event of a termination of the Merger Agreement.
• Risks that the milestones related to the contingent value rights (CVRs) are not achieved, resulting in no or reduced CVR payments.
• Potential for disruption caused by the transaction, making it more difficult to maintain relationships with employees, collaborators, vendors, and other business partners.
• Risks related to diverting management's attention from scPharmaceuticals' ongoing business operations.
• The risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Risks pertaining to scPharmaceuticals' business, including its dependence on the commercial success of FUROSCIX and, if approved, its other product candidates.
• Risks related to the receipt of regulatory approval for scPharmaceuticals' product candidates.
• Risks related to scPharmaceuticals' ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization.
• Risks related to scPharmaceuticals' history of operating losses and the potential need for additional funding, which may not be available when needed.
• Restrictions on operating and financial flexibility imposed by scPharmaceuticals' credit facility and revenue participation financing facility.
• Risks associated with clinical and preclinical development, which is a lengthy and expensive process with uncertain outcomes.
• The risk that global economic factors and uncertainties will impact scPharmaceuticals' operations.

Future Outlook

MannKind anticipates diversifying its revenue streams and accelerating double-digit growth over the next decade. This growth is expected to be driven by its expanded portfolio of commercial products, including Afrezza (with an adult label update and pediatric sBLA submission), FUROSCIX (with an autoinjector sNDA submission planned for Q3 2025), and V-Go. The company also expects upcoming data readouts from the TETON 1 and 2 studies of Tyvaso in idiopathic pulmonary fibrosis (IPF) and plans to initiate a Phase 2 clinical trial for nintedanib DPI (MNKD-201) for IPF by year-end 2025, further advancing its late-stage pipeline.

Management Comments

• Michael Castagna, CEO of MannKind Corporation: "This acquisition expands our patient-centered brands and highlights MannKind’s dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases. With multiple anticipated product launches and indication expansions, we expect to continue to diversify our revenue streams and accelerate our double-digit growth goals over the next decade."
• John Tucker, CEO of scPharmaceuticals: "This transaction with MannKind represents an exciting next chapter for scPharmaceuticals and the FUROSCIX brand. By combining our innovative products with MannKind’s proven commercial capabilities and shared commitment to advancing patient care, we believe MannKind can accelerate access to important therapies and create meaningful value for patients, providers, and stockholders."

Industry Context

This acquisition marks MannKind's strategic entry into the cardiorenal medicine market, complementing its existing focus on orphan lung diseases. By integrating scPharmaceuticals' FUROSCIX, MannKind is expanding its therapeutic portfolio and leveraging its commercial infrastructure to tap into a significant market opportunity, particularly in chronic kidney disease. This move aligns with broader pharmaceutical industry trends of strategic M&A to diversify revenue streams, acquire innovative therapies, and optimize commercial reach by leveraging existing sales channels for new indications or acquired products.

Management Changes

Corporate Governance

Legal Proceedings

• No Legal Proceeding or governmental or administrative investigation, audit, inquiry, or action is pending or, to the Knowledge of the Company, threatened against scPharmaceuticals or its Subsidiary that would reasonably be expected to have a Company Material Adverse Effect.
• No Legal Proceeding is pending or, to the Knowledge of the Company, threatened seeking to impose any legal restraint on or prohibition against the Transactions.
• The filing acknowledges a risk of stockholder litigation in connection with the transactions contemplated by the Merger Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• No current director, officer, or controlled Affiliate of scPharmaceuticals has outstanding indebtedness to the Company.
• No current director, officer, or controlled Affiliate of scPharmaceuticals is a party to, or directly or indirectly benefits from, any Contract, transaction, agreement, arrangement, or understanding with the Company (other than a Plan) of a type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.

Stakeholder Impact

• **Shareholders (scPharmaceuticals)**: Will receive a significant premium for their shares, consisting of $5.35 in cash per share plus contingent value rights up to $1.00 per share, representing a favorable exit.
• **Shareholders (MannKind)**: The acquisition is expected to diversify MannKind's revenue base and accelerate its double-digit growth goals, potentially enhancing long-term shareholder value.
• **Employees (scPharmaceuticals)**: Continuing employees are guaranteed annual base salary/hourly wage rates and cash bonus/incentive opportunities no less favorable than prior to the Effective Time, and comparable defined contribution retirement, health, welfare, and employee benefits until December 31, 2026. However, directors and officers will resign effective at the Effective Time.
• **Customers/Patients**: The combined entity aims to accelerate access to important therapies, particularly FUROSCIX, for patients with cardiometabolic and orphan lung diseases, potentially improving patient care.
• **Suppliers/Vendors**: The transaction may cause disruption, making it more difficult to maintain relationships with vendors and business partners, though MannKind aims to preserve business organization.
• **Creditors**: scPharmaceuticals' existing credit facility and revenue participation financing facility will be repaid and bought out, respectively, upon the closing of the transaction.

Next Steps

• Purchaser (MannKind's subsidiary) will commence a tender offer within ten business days from August 24, 2025.
• The tender offer will remain open for twenty business days, subject to possible extensions under the terms of the Merger Agreement.
• Parent and Purchaser will file a tender offer statement on Schedule TO with the SEC.
• scPharmaceuticals will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Following the successful completion of the tender offer, Purchaser will merge with and into scPharmaceuticals, with scPharmaceuticals continuing as the surviving wholly-owned subsidiary of MannKind.
• The FUROSCIX ReadyFlow Autoinjector is on track for a supplemental New Drug Application (sNDA) submission in Q3 2025.
• Upcoming readouts from the TETON 1 and 2 studies of Tyvaso in idiopathic pulmonary fibrosis (IPF) are anticipated.
• Nintedanib DPI (MNKD-201) is expected to initiate a Phase 2 clinical trial for IPF by year-end 2025.
• scPharmaceuticals shares will be delisted from NASDAQ, and its registration under the Exchange Act will be terminated as promptly as practicable after the Effective Time.

Key Dates

Recommendation

The acquisition provides a substantial premium to scPharmaceuticals shareholders, indicating a favorable exit. For MannKind, it represents a highly strategic move to diversify its revenue base with a rapidly growing, FDA-approved product (FUROSCIX) in a large and underserved market (cardiometabolic diseases). The planned sNDA for the autoinjector could significantly expand market opportunity. The financing for the acquisition is secured, and the deal is supported by key scPharmaceuticals shareholders. While CVRs introduce some contingent risk, the overall strategic fit and immediate financial benefits are compelling for MannKind's long-term growth and market position.

Keywords

MannKind, scPharmaceuticals, Merger, Acquisition, Tender Offer, FUROSCIX, Cardiometabolic, Chronic Heart Failure, Chronic Kidney Disease, CVR, Contingent Value Right, FDA Approval, Net Sales, Pharmaceutical, Biotechnology, Healthcare, M&A, MNKD, SCPH